Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Organisation › Details

iOnctura (Group)

iOnctura BV, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merckand funded by M Ventures. It is a clinical stage biotechnology company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer. Each of iOnctura’s programs harness the combined effect of immune-mediated and direct anti-tumour activity and aim to deliver molecules with superior clinical efficacy and safety in oncology. The company’s lead program, IOA-244, will enter the clinic in Q1 2020. The study is aimed to clinically demonstrate for the first time that a highly selective PI3Kd inhibition not only drives an immunemediated response but also a direct anti-tumoural effect in a stratified patient population across multiple solid tumour indications. The Company’s second molecule is a novel autotaxin (ATX) inhibitor at IND stage for patients with solid tumours burdened with cancer-associated fibrosis. *

 

Period Start 2017-06-20 established (s-off
  Predecessor Merck KGaA
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 drug development
Person Person Pickering, Catherine (iOnctura 201706– CEO + Co-Founder before Merck Head Global Oncology Licensing + BusDev)
     
Region Region Genève (Geneva) GE
  Country Switzerland
  Street 15 Avenue Sécheron
Campus Biotech Innovation Park, Bâtiment F2
  City 1202 Genève GE
    Address record changed: 2020-01-27
     
Basic data Employees n. a.
     
    * Document for �About Section�: iOnctura B.V.. (1/23/20). "Press Release: iOnctura Raises EUR 15 Million in Series A Financing to Progress Its Pipeline into Clinical Development". Amsterdam.
     
   
Record changed: 2020-01-27

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for iOnctura (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top